Diabetic Foot Ulcer Clinical Trial
Official title:
Efficacy of the Er:YAG Laser Debridement on Patient-Reported Pain and Bacterial Load in Chronic Wounds
Bacterial load is frequently associated with impaired healing of chronic wounds. As well, sharp debridement is often associated with pain, causing patient distress, and thereby occasionally contributing to inadequacy of debridement, leading to a delay in wound healing. The purpose of this study is to assess the efficacy of the Sciton Laser in reducing bacterial load and patient distress in patients with chronic wounds, in efforts to expedite the wound healing process.
Chronic wounds are a debilitating affliction, affecting a substantial portion of the
population worldwide and incurring staggering healthcare economic costs (1,2). Included among
chronic wounds are venous leg ulcers, which are known to cause considerable pain, and can
impact patient quality of life, thereby complicating wound care (3). The exact
pathophysiology and etiology of the prolonged course of chronic wounds are poorly understood,
but are thought to be multi-factorial in nature. Given the exposure of chronic wounds to the
environment, they harbor a diverse microbial flora. Specifically, there is evidence that
biofilm produced by these microbes are a large contributor to their non-healing nature (4).
Debridement is considered an integral part of wound management with its ability to remove
necrotic tissue and bacterial biofilm, in addition to stimulating release of cytokines and
growth factors that promote wound healing (5). However, sharp debridement, the gold standard
in wound care, is often ineffective for painful wounds.
The effect of lasers on wound healing have been well-studied both in in vitro and in vivo
models. Beneficial effects of low-level laser therapy in wound healing in animal and human
studies has been established. However, extrapolation of this data is limited by study design
and light dosimetry (6). Laser energy used for surgical excision is a lesser-known
debridement technique that has been largely limited to burn scar treatment (7,8,9,10). Lasers
are electro-optical devices that emit a focused beam of intense monochromatic light in the
visible and infrared radiation spectrums. Since their start in the 1960s, lasers have been
successfully utilized in many fields of medicine. Lasers for wound debridement began in the
1970s, with the successful report of a continuous-beam carbon dioxide (CO2) laser used for
skin graft preparation of infected decubitus ulcers (11). Laser debridement is based on the
controlled vaporization of the superficial layers of the wound bed. This results in the
removal of the tissue containing unwanted microbial and necrotic particles. The laser type
and the number of passes performed determine the depth of tissue ablation (12). Unlike other
methods dependent on the clinician's manual control, laser debridement is electronically
controlled, improving precision and reducing the risk of healthy tissue damage. Advantages of
laser debridement include precision and uniformity of tissue ablation, which reduces trauma
to the wound bed, improving patient comfort. To reduce thermal damage to healthy tissue,
several improvements in laser technology have been made over the years. By utilizing a
pulsed-beam system, laser energy is delivered in high-power, rapid succession pulses,
resulting in short duration and high temperature exposure of target tissue, thereby
minimizing thermal injury.
Erbium:YAG (Er:YAG) lasers, with a wavelength of 2940-nm are widely used in the dermatologic
community for skin resurfacing, for anti-aging and acne-related purposes (13). Skin ablation
with the erbium laser is very precise, and allows for accurate assessment of the resurfacing
depth (12,14,15). Since Er:YAG laser energy has greater than twelve times more water
absorption efficiency than CO2 lasers, water in the tissue is rapidly expanded to eject the
charred debris from the wound surface without leaving behind a necrotic eschar (12,16,17).
The Er:YAG laser provides distinct advantages in precise ablation control and the reduction
of residual necrotic tissue burden with minimal procedural discomfort, making the Er:YAG
laser the most suitable device for laser wound debridement. Preliminary studies demonstrate
remarkable patient pain reduction after laser debridement, resulting in more thorough removal
of necrotic tissue and biofilm/bacterial load. Additionally, the extent of laser debridement
is determined by the laser settings, as opposed to the individual operator's dexterity and
skill, thereby providing better control over the wound bed preparation, producing more
predictable and reproducible outcomes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04497805 -
Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers
|
Phase 2 | |
Withdrawn |
NCT03675269 -
Adjunctive Hyperbaric Oxygen Therapy (HBOT) for Lower Extermity Diabetic Ulcer:
|
N/A | |
Completed |
NCT04624516 -
Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence
|
N/A | |
Not yet recruiting |
NCT06439667 -
VIRTUALLY SUPERVISED TELE-EXERCISE PLATFORM FOR ACCELERATING PLANTAR WOUND HEALING
|
||
Recruiting |
NCT05608187 -
Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers
|
Phase 2 | |
Not yet recruiting |
NCT06437028 -
Evaluating the Efficacy of Perinatal Membrane Allografts for the Treatment of Diabetic Foot Ulcers.
|
N/A | |
Not yet recruiting |
NCT06278935 -
Lifestyle Tailored Offloading for Diabetic Foot Ulcers
|
N/A | |
Withdrawn |
NCT05024656 -
AmnioExcel® Plus vs SOC in the Management of Diabetic Foot Ulcers
|
N/A | |
Terminated |
NCT02202668 -
Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers
|
N/A | |
Terminated |
NCT01966380 -
Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia
|
Phase 2 | |
Completed |
NCT01951768 -
Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection
|
Phase 4 | |
Completed |
NCT01657474 -
Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers
|
N/A | |
Active, not recruiting |
NCT00389636 -
TheraGauzeā¢ Alone and Regranex®Gel 0.01% Plus TheraGauzeā¢ in the Treatment of Wagner Stage I Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT01181440 -
Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers
|
Phase 3 | |
Enrolling by invitation |
NCT05888259 -
Plantar Pressure Distribution in Diabetic Foot Ulcer
|
N/A | |
Completed |
NCT04054804 -
Digital Foot Check by Using the D-Foot, a New Software
|
||
Not yet recruiting |
NCT05877378 -
Efficacy of PICO Single-use System in Chronic Ulcers
|
N/A | |
Recruiting |
NCT06037369 -
The Short Message-based Customized Standardized
|
N/A | |
Completed |
NCT03312595 -
Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)
|
N/A | |
Recruiting |
NCT04564443 -
A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot
|
N/A |